Maia Biotech wins Spanish, Portuguese regulatory clearance to screen patients in THIO-104 lung cancer trial

Bitget2026/09/23 13:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Maia Biotechnology won regulatory clearance in Spain, Portugal to start screening for its Phase 3 THIO-104 NSCLC trial.
AEMPS, INFARMED authorizations extend the pivotal study’s European footprint ahead of a planned 2027 interim survival analysis.
Trial enrolled 65 patients to date; target is 100 dosed by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230917PRIMZONEFULLFEED9831706) on September 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Maia Biotech wins Spanish, Portuguese regulatory clearance to screen patients in THIO-104 lung cancer trial

You may also like

Crypto prices